proinflammatory cytokines tumor necrosis factor treatment septic shock syndrome septic shock syndrome antibodies endotoxin limitations Other targets septic shock antibodies complement fragment platelet-activating factor antagonists blockade endothelial cell leukocyte adhesion molecules Specific blockade proinflammatory cytokines tumor necrosis factor TNF morbidity mortality septic shock TNF uses diseases septic shock Use antibodies receptors consequences infection inflammation lethal outcomes animal models receptor antagonist natural-occurring cytokine blocks shock death due Escherichia coli variety inflammatory diseases Soluble TNF surface receptors respective cytokines ameliorate disease Current clinical trials safety efficacy anticytokine therapies 